Treatment of systemic lupus erythematosus with epratuzumab

被引：50

作者：

Traczewski, Pawel ^{[1
]}

Rudnicka, Lidia ^{[1
,2
]}

机构：

[1] Dept Dermatol CSK MSWiA, PL-02507 Warsaw, Poland

[2] Warsaw Med Univ, Div Publ Hlth, Warsaw, Poland

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2011年 / 71卷 / 02期

关键词：

epratuzumab; monoclonal antibody; rituximab; SLE; systemic lupus erythematosus; HUMANIZED ANTI-CD22 ANTIBODY; NON-HODGKINS-LYMPHOMA; B-CELL DEPLETION; PHASE-I/II TRIAL; MONOCLONAL-ANTIBODY; DOUBLE-BLIND; CLINICAL-TRIAL; CD22; THERAPY; RITUXIMAB;

D O I：

10.1111/j.1365-2125.2010.03767.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Systemic lupus erythematosus is a prototypic autoimmune disease characterized by abnormalities in the activity of B-cells and T-cells. A novel specific treatment for autoimmune diseases is B-cell depletion with monoclonal antibodies. Epratuzumab is a monoclonal antibody that targets CD22 antigen on B-cells. Initial phase II and two terminated early phase III studies suggest that treatment of systemic lupus erythematosus with this immunomodulatory agent is effective, well tolerated and significantly improves the patient's quality of life. In vitro studies and clinical trials with non-Hodgkin lymphoma patients indicate epratuzumab can potentially serve as a complementary drug in combination therapy with another inhibitor of B-cell activity, rituximab, which is a monoclonal anti-CD20 antibody.

引用

页码：175 / 182

页数：8

共 60 条

[31] Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma [J].

Leonard, JP ;

Coleman, M ;

Ketas, JC ;

Chadburn, A ;

Ely, S ;

Furman, RR ;

Wegener, WA ;

Hansen, HJ ;

Ziccardi, H ;

Eschenberg, M ;

Gayko, U ;

Cesano, A ;

Goldenberg, DM .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (16) :3051-3059

[32]

Leonard JP, 2002, BLOOD, V100, p358A

[33] Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: Phase I/II clinical trial results [J].

Leonard, JP ;

Coleman, M ;

Ketas, JC ;

Chadburn, A ;

Furman, R ;

Schuster, MW ;

Feldman, EJ ;

Ashe, M ;

Schuster, SJ ;

Wegener, WA ;

Hansen, HJ ;

Ziccardi, H ;

Eschenberg, M ;

Gayko, U ;

Fields, SZ ;

Cesano, A ;

Goldenberg, DM .

CLINICAL CANCER RESEARCH, 2004, 10 (16) :5327-5334

[34] ROLE OF INTERLEUKIN-10 IN THE B-LYMPHOCYTE HYPERACTIVITY AND AUTOANTIBODY PRODUCTION OF HUMAN SYSTEMIC LUPUS-ERYTHEMATOSUS [J].

LLORENTE, L ;

ZOU, WP ;

LEVY, Y ;

RICHAUDPATIN, Y ;

WIJDENES, J ;

ALCOCERVARELA, J ;

MORELFOURRIER, B ;

BROUET, JC ;

ALARCONSEGOVIA, D ;

GALANAUD, P ;

EMILIE, D .

JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 181 (03) :839-844

[35] A perspective on B-cell-targeting therapy for SLE [J].

Looney, R. John ;

Anolik, Jennifer ;

Sanz, Inaki .

MODERN RHEUMATOLOGY, 2010, 20 (01) :1-10

[36] B cell depletion as a novel treatment for systemic lupus erythematosus - A phase I/II dose-escalation trial of rituximab [J].

Looney, RJ ;

Anolik, JH ;

Campbell, D ;

Felgar, RE ;

Young, F ;

Arend, LJ ;

Sloand, JA ;

Rosenblatt, J ;

Sanz, I .

ARTHRITIS AND RHEUMATISM, 2004, 50 (08) :2580-2589

[37] Role of B cells in systemic lupus erythematosus and rheumatoid arthritis [J].

Mandik-Nayak, Laura ;

Ridge, Natalie ;

Fields, Michele ;

Park, Audrey Y. ;

Erikson, Jan .

CURRENT OPINION IN IMMUNOLOGY, 2008, 20 (06) :639-645

[38] Toll-like receptors in systemic autoimmune disease [J].

Marshak-Rothstein, Ann .

NATURE REVIEWS IMMUNOLOGY, 2006, 6 (11) :823-835

[39] Dysregulated expression of the Cd22 gene as a result of a short interspersed nucleotide element insertion in Cd22a lupus-prone mice [J].

Mary, C ;

Laporte, C ;

Parzy, D ;

Santiago, ML ;

Stefani, F ;

Lajaunias, F ;

Parkhouse, RME ;

O'Keefe, TL ;

Neuberger, MS ;

Izui, S ;

Reininger, L .

JOURNAL OF IMMUNOLOGY, 2000, 165 (06) :2987-2996

[40]

McCluskey G, 2008, ANN RHEUM DIS, V67, P469

← 1 2 3 4 5 6 →